Johnson & Johnson (NYSE:JNJ) received FDA approval for its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract patients. The lens is described as the first of its kind in the ...
GlobalData on MSN
FDA approves J&J’s TECNIS PureSee intraocular lens
The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.
The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release ...
The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...
Primary IOL implantation in pediatric open globe injuries with active inflammation showed inferior visual outcomes compared ...
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients ...
Johnson & Johnson (NYSE: JNJ) announced that it received FDA approval for its Tecnis PureSee intraocular lens (IOL) for cataract surgery.
CPT copyright 2011 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Editor’s Note: This article ...
The Outpatient Ophthalmic Surgery Society conducted a survey of intraocular lens procedures in an ASC setting and published the results in The Ophthalmic ASC. The survey gathered results from 146 ...
Randomization (2:1:1) compared 78 mcg or 39 mcg BIM-IOL plus artificial tears versus standard monofocal IOL plus twice-daily timolol, with IOP change assessed at early visits. Mean IOP reduction at 12 ...
FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results